Clinical trials: Pandemic Response
Influenza
Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults
This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 18 to 64 years of age.
- Trial name
- NCT01008956
- Testing
- GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
The aim of this study is to evaluate the safety, reactogenicity and immunogenicity of the Flu Pandemic messenger RNA (mRNA) vaccine (including dose-finding and dose-confirmation) administered in healthy adults 18 to 85 years of…
- Trial name
- NCT06382311
- Testing
- Flu Pandemic mRNA_Dose level 1, Flu Pandemic mRNA_Dose level 2, Flu Pandemic mRNA_ Dose level 3.
- Where
- 21 sites in United States
- Volunteers
- 991 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Mother-Child Interaction
Effects of Contact Restrictions During the COVID-19 Pandemic on Newborns and Their Parents
In the study, the researchers aim to investigate the impact of contact restrictions during the pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on newborns…
- Trial name
- NCT04732702
- Testing
- no intervention
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- University of Cologne
Influenza
Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old
This study is designed to characterize the safety and immunogenicity of pandemic influenza (H1N1) candidate vaccines GSK2340274A and GSK234072A in children 3 to less than 10 years old.
- Trial name
- NCT01161160
- Testing
- GSK Biologicals' GSK2340274A (two different formulations), GSK Biologicals' - GSK2340272A
- Where
- 2 sites in Philippines, Thailand
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Virus Diseases
Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults
Avian influenza (AI), or bird flu, has recently become a major health concern in Asia and other parts of the world. The need for a vaccine to prevent the spread of AI among livestock and to humans is sorely needed.
- Trial name
- NCT00347672
- Testing
- H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID19
Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic
The SARS-CoV-2 pandemic has resulted in an international shortage of the nasopharyngeal (NP) swabs used to collect sample for virological testing.
- Trial name
- NCT04368260
- Testing
- Control swab, Prototype swab
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Influenza, Virus Diseases
Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine
In the 20th century, influenza pandemics occurred in 1918, 1957, and 1968, and were associated with significant morbidity and mortality.
- Trial name
- NCT00722774
- Testing
- H2N2 1960 AA ca recombinant vaccine
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Virus Diseases
Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)
Avian influenza (AI), or bird flu, has recently become a major health concern in Asia and other parts of the world. The purpose of this study is to test the safety of and immune response to a new AI vaccine in healthy adults.
- Trial name
- NCT00110279
- Testing
- H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Paediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-Cov-2
Paediatric Inflammatory Multisystem Syndrome During COVID-19 Pandemic
During the COVID-19 pandemic, a small minority of children have been presenting to acute paediatric services with a new syndrome, Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS-Cov-2 (PIMS-TS).
- Trial name
- NCT04761913
- Where
- 6 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Anglia Ruskin University
Cancer, COVID-19
The COVID-IYON Study - Study Examining Data Pertaining to Clinical Outcomes and Organisational Responses to the 2020 SARS-CoV-2 Pandemic"
This is a prospective, multisite, descriptive, observational clinical/epidemiological study examining both quantitative and qualitative data pertaining to clinical outcomes and organizational responses to the 2020…
- Trial name
- NCT04581070
- Where
- 3 sites in Ireland
- Volunteers
- 4 people
- Sponsor
- Cancer Trials Ireland
COVID-19 Infection
Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The global outbreak of COVID-19 is a major public health problem. COVID-19 causes a wide range of symptoms.
- Trial name
- NCT04582903
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Stress, Anxiety
Post-Pandemic Perception of Public Space in Singapore
In this study it is aimed to investigate the difference between the brain response to different urban environments in Singapore before and after the COVID-19 pandemic.
- Trial name
- NCT04394039
- Testing
- Public space exposure
- Where
- Singapore
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- National University of Singapore
Influenza, Human
Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines
This study seeks to understand the host factors that affect the replication and immune response of seasonal and candidate pandemic live attenuated influenza vaccine (LAIV) in humans and to develop biomarkers that can predict the…
- Trial name
- NCT01674205
- Testing
- A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca), A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca), 2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19
Response of Korean Medicine Hospital to COVID-19
The objectives of this study are to report the response strategy to prevent COVID-19 spread implemented at a Korean medicine hospital, and the satisfaction survey results regarding its preventive measures.
- Trial name
- NCT04529447
- Testing
- Survey
- Where
- South Korea
- Volunteers
- 485 people, healthy volunteers welcome
- Sponsor
- Jaseng Hospital of Korean Medicine
Influenza A Virus, H1N1 Subtype
Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff.
This project may help to answer several fundamental questions related to public health regarding vaccination against influenza viruses and regarding the influenza A(H1N1)v pandemy: What is the immunologic efficacy in terms of…
- Trial name
- FLU-HOP (NCT01063608)
- Testing
- Anti-H1N1v Vaccine
- Where
- 2 sites in France
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Acute Respiratory Failure, COVID-19
REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19: REHSCU Study
The worldwide COVID-19 pandemic has led to a dramatic increase in the number of patients hospitalized in intensive care units for an acute respiratory failure in all countries.
- Conditions
- Acute Respiratory Failure, COVID-19, Trauma, Stroke
- Trial name
- REHSCU (NCT04611425)
- Testing
- Remimazolam
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital
Diagnostics, Pandemic Response
High-throughput Serological Testing of Antibodies Platform
In the case of large emergency serosurveys, innovation in the sampling techniques is an often neglected, but relevant aspect to facilitate the enrolment of subjects in both adult and paediatric populations.
- Trial name
- DEVHISE (NCT06939556)
- Where
- 2 sites in Italy
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Istituto Zooprofilattico Sperimentale delle Venezie
Influenza, Virus Diseases
Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults
Over the past decade, avian influenza (AI) has become a major health concern. The development of a safe and effective vaccine against H5N1 infection is important.
- Trial name
- NCT00488046
- Testing
- H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults
This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 19 to 40 years who have never received influenza vaccination.
- Trial name
- NCT01059617
- Testing
- GSK Biologicals' FluLaval®, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
- Where
- 3 sites in United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Covid19
Minimizing the Effects of COVID-19 Hospitalization With the COVID Rehabilitation Program for the Elderly
Although evidence from the management of other viral respiratory infections suggest that early multidisciplinary rehabilitation could mitigate the adverse effects of the severe form of the illness, and reduce the length of…
- Trial name
- CORE (NCT04771052)
- Testing
- COVID Rehabilitation Program for the Elderly (CORE)
- Where
- 2 sites in Canada
- Volunteers
- 124 people
- Sponsor
- Université de Sherbrooke